PriceTargets.com logo

Zealand Pharma A/S - ZEAL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$17.59 As of 10/7/2022 01:00 AM ET
+0 (0.00%)
Get New Zealand Pharma A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZEAL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZEAL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Zealand Pharma A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $17.59.

This chart shows the closing price for ZEAL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Zealand Pharma A/S. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2024Berenberg BankInitiated CoverageBuyN/A
11/16/2022Morgan StanleyDowngradeOverweight ➝ Equal WeightN/A
9/9/2022Morgan StanleyInitiated CoverageOverweightLow
1/11/2022Jefferies Financial GroupUpgradeHold ➝ BuyLow
11/13/2020Morgan StanleyLower TargetOverweight$45.00 ➝ $44.00Low
10/13/2020Morgan StanleyBoost TargetOverweight$43.00 ➝ $45.00Medium
8/14/2020Morgan StanleyBoost TargetOverweight$40.00 ➝ $43.00High
8/13/2020Needham & Company LLCInitiated CoverageBuy$42.00High
7/15/2020Morgan StanleyBoost TargetOverweight$37.00 ➝ $40.00Low
5/14/2020Needham & Company LLCInitiated CoverageBuy$42.00High
4/15/2020Morgan StanleyBoost TargetOverweight$35.00 ➝ $37.00Low
3/31/2020Morgan StanleyLower TargetOverweight$38.00 ➝ $35.00Medium
3/13/2020Needham & Company LLCReiterated RatingBuyHigh
3/10/2020Morgan StanleyReiterated RatingBuy$38.00High
2/10/2020Needham & Company LLCReiterated RatingBuy$42.00Low
1/17/2020Morgan StanleyBoost TargetOverweight$35.00 ➝ $38.00Low
11/27/2019Jefferies Financial GroupDowngradeBuy ➝ HoldLow
11/19/2019Jefferies Financial GroupDowngradeBuy ➝ HoldMedium
11/15/2019Needham & Company LLCBoost TargetBuy$32.00 ➝ $42.00High
10/15/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$41.00High
9/19/2019GuggenheimInitiated CoverageBuyHigh
9/18/2019Needham & Company LLCSet TargetBuy$32.00Low
8/19/2019Morgan StanleyBoost TargetOverweight$29.00 ➝ $30.00Low
8/15/2019Needham & Company LLCReiterated RatingBuy$29.00 ➝ $32.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

-0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/15/2024
  • 1 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/16/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
4/15/2024

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Zealand Pharma A/S logo
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $17.59
Low: $17.59
High: $17.59

50 Day Range

MA: $17.67
Low: $16.54
High: $19.20

52 Week Range

Now: $17.59
Low: $9.93
High: $32.94

Volume

N/A

Average Volume

4,965 shs

Market Capitalization

$818.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Zealand Pharma A/S?

The following Wall Street analysts have issued stock ratings on Zealand Pharma A/S in the last year: Berenberg Bank.
View the latest analyst ratings for ZEAL.

What is the current price target for Zealand Pharma A/S?

0 Wall Street analysts have set twelve-month price targets for Zealand Pharma A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Zealand Pharma A/S in the next year.
View the latest price targets for ZEAL.

What is the current consensus analyst rating for Zealand Pharma A/S?

Zealand Pharma A/S currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZEAL will outperform the market and that investors should add to their positions of Zealand Pharma A/S.
View the latest ratings for ZEAL.

What other companies compete with Zealand Pharma A/S?

Other companies that are similar to Zealand Pharma A/S include Tango Therapeutics, Enliven Therapeutics, Aerovate Therapeutics, Nurix Therapeutics and Disc Medicine. Learn More about companies similar to Zealand Pharma A/S.

How do I contact Zealand Pharma A/S's investor relations team?

Zealand Pharma A/S's physical mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company's listed phone number is (458) 877-3600 and its investor relations email address is [email protected]. The official website for Zealand Pharma A/S is www.zealandpharma.com. Learn More about contacing Zealand Pharma A/S investor relations.